Written By Varun Viswapriyan
Edited By Matilda Khachikyan The fight against cancer hinges on early detection. The earlier a malignancy is identified, the better the chances are of successful treatment. While traditional screening methods like mammograms and colonoscopies remain crucial, wearable technology offers a new frontier in proactive cancer detection. These monitoring devices hold promise for identifying subtle physiological changes that might signal the early stages of cancer development.
One area of exploration is the use of smart bras that are equipped with ultrasound technology. A prototype, which is under development by MIT researchers, is a flexible patch that adheres to a bra and allows users to perform self-scans of their breast tissue. This non-invasive approach could encourage women, particularly those at high risk for breast cancer, to monitor their health more frequently than traditional mammograms, which typically occur every one to two years. Early detection of interval cancers – those that develop between mammograms – could be significantly improved with such technology. Research suggests that interval cancers account for up to 30% of all breast cancers diagnosed.
Image Courtesy of healthcare-in-europe.com
Another avenue of exploration involves wearable devices that track skin health. Melanoma, which is the deadliest form of skin cancer, is highly treatable when detected early. A 2020 study published in Nature Communications described a smartwatch attachment that uses multispectral imaging to analyze skin lesions. The study found that the device achieved an accuracy of over 80% in differentiating between benign and malignant moles. Widely adopted wearable skin monitors could potentially cause individuals to be more vigilant about suspicious moles and in turn, seek prompt medical evaluation.
Image Courtesy of MDPI
Beyond specific cancer types, wearable biosensors hold promise for flagging general physiological changes that might be indicative of underlying malignancies. These sensors can monitor a range of parameters including, heart rate, sleep patterns, and even blood sugar levels. A 2021 study published by Oncology found that wearable data collected over a year revealed distinct sleep and activity patterns in lung cancer patients compared to healthy controls. While such data may not provide a definitive diagnosis, it could prompt individuals to seek further investigation and potentially lead to earlier cancer detection.
Despite the exciting potential, wearable tech for early cancer detection remains in its nascent stages. Rigorous clinical trials are needed to validate the efficacy of these devices and establish their role in traditional screening protocols. Additionally, concerns regarding data privacy and the potential for misinterpretations of sensor data need to be addressed.
Image Courtesy of CancerGRACE
In conclusion, wearable technology presents a fascinating new front in the battle against cancer. From monitoring specific tissues for abnormalities to flagging broader physiological changes, these devices hold immense promise for empowering individuals to take a more proactive approach to their health. Continued research and development, coupled with careful consideration of privacy and data security, are crucial to translating the potential of wearable tech into a reality that saves lives.
References
1. Nurse Journal. (n.d.). MIT Researchers Develop A Wearable Breast Cancer Detection Device. Retrieved May 22, 2024, from https://news.mit.edu/2023/wearable-ultrasound-scanner-breast-cancer-0728
2. Newswise. (n.d.). Wearable ultrasound scanner could detect breast cancer earlier. Retrieved May 22, 2024, from https://news.mit.edu/2023/wearable-ultrasound-scanner-breast-cancer-0728
3. Yu, L., Xu, L., Gai, X., Huang, J., Wang, P., Gong, S., ... & Cheng, H. (2020). A wearable multispectral imaging device for non-invasive skin cancer screening. Nature Communications,
4. Sheng, L., He, Y., Jin, Z., He, Y., Li, Y., & Jin, X. (2021). Wearable sensor data analysis for lung cancer detection: Real-world study. npj Oncology, 7(1), 1-9.
Comments